| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2013 | US20130196961 Combinations comprising antimuscarinic agents and corticosteroids |
| 08/01/2013 | US20130196960 Cannabinoid Receptor Agonists |
| 08/01/2013 | US20130196959 Topical steroidal formulations |
| 08/01/2013 | US20130196958 Methods of nourishing animals |
| 08/01/2013 | US20130196957 Roll-on with high salicylic acid content |
| 08/01/2013 | US20130196956 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 08/01/2013 | US20130196955 Polymorphisms for predicting disease and treatment outcome |
| 08/01/2013 | US20130196954 Method of treating acne |
| 08/01/2013 | US20130196951 Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| 08/01/2013 | US20130196950 Retinoid replacements and opsin agonists and methods for the use thereof |
| 08/01/2013 | US20130196949 Hydroxyalkyl starch in combination with cytostatica for the treatment of cancers by reduction of tumor growth rates |
| 08/01/2013 | US20130196947 Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases |
| 08/01/2013 | US20130196945 Cyclodextrin-based polymers for therapeutics delivery |
| 08/01/2013 | US20130196942 Composition for Skin Treatment |
| 08/01/2013 | US20130196939 Detection of dna sequences as risk factors for hiv infection |
| 08/01/2013 | US20130196938 Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 08/01/2013 | US20130196937 Age production inhibitor |
| 08/01/2013 | US20130196936 N-acetyl mannosamine as a therapeutic agent |
| 08/01/2013 | US20130196935 Synthetic glycoamine compounds |
| 08/01/2013 | US20130196934 Composition for perinatal and neonatal stroke |
| 08/01/2013 | US20130196907 Promoting Erythropoietin, Erythrocyte, and Hematopoietic Stem Cell Production By Activating HIF In OsteoBlasts |
| 08/01/2013 | US20130196900 Enhancement of innate resistance to infection |
| 08/01/2013 | US20130196898 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| 08/01/2013 | US20130196849 Substituted Cellulose Acetates and Uses Thereof |
| 08/01/2013 | US20130196342 Compositions And Methods For Modulating S-Nitrosogluthione Reductase |
| 08/01/2013 | US20130196012 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 08/01/2013 | US20130196008 Products Containing Highly Unsaturated Fatty Acids for Use by Women and Their Children During Stages of Preconception, Pregnancy and Lactation/Post-Partum |
| 08/01/2013 | US20130196005 Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
| 08/01/2013 | US20130196002 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| 08/01/2013 | US20130196000 Combination therapy including isophosphoramide mustard, analogs, or salts thereof |
| 08/01/2013 | US20130195998 Therapeutic compositions |
| 08/01/2013 | US20130195992 Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
| 08/01/2013 | US20130195985 Composition Comprising SOD, Lutein and Zeaxanthin |
| 08/01/2013 | US20130195984 Combinations and modes of administration of therapeutic agents and combination therapy |
| 08/01/2013 | US20130195982 Non-abusable pharmaceutical composition comprising opioids |
| 08/01/2013 | US20130195981 Non-abusable pharmaceutical composition comprising opioids |
| 08/01/2013 | US20130195977 Low Concentration Meloxicam Tablets |
| 08/01/2013 | US20130195976 Pharmaceutical composition for the treatment of acute disorders |
| 08/01/2013 | US20130195975 In vivo use of water absorbent polymers |
| 08/01/2013 | US20130195973 Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| 08/01/2013 | US20130195972 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| 08/01/2013 | US20130195967 Liver specific delivery of messenger rna |
| 08/01/2013 | US20130195960 Substituted Cellulose Acetates and Uses Thereof |
| 08/01/2013 | US20130195957 Patch and method for enhancing adhesion force of the same |
| 08/01/2013 | US20130195954 Films and particles |
| 08/01/2013 | US20130195953 Methods and formulations for administration of anti-inflammatory compounds |
| 08/01/2013 | US20130195951 Heterogeneous implantable devices for drug delivery |
| 08/01/2013 | US20130195950 Heterogeneous implantable devices for drug delivery |
| 08/01/2013 | US20130195944 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists |
| 08/01/2013 | US20130195943 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists |
| 08/01/2013 | US20130195939 Methods and compositions for oral administration of exenatide |
| 08/01/2013 | US20130195937 Use of carbon nanotubes for preventing or treating brain disease |
| 08/01/2013 | US20130195936 Ophthalmic oil-in-water emulsions containing prostaglandins |
| 08/01/2013 | US20130195935 Abuse-proofed dosage form |
| 08/01/2013 | US20130195934 Methods and devices for providing prolonged drug therapy |
| 08/01/2013 | US20130195926 Modulation of nitric oxide signaling to normalize tumor vasculature |
| 08/01/2013 | US20130195922 Methods and compositions for treating proliferative diseases |
| 08/01/2013 | US20130195896 Compositions and methods for the treatment of a neoplasia |
| 08/01/2013 | US20130195894 Detection and treatment of autoimmune disorders |
| 08/01/2013 | US20130195891 Micro-RNA family that Modulates Fibrosis and Uses Thereof |
| 08/01/2013 | US20130195890 Treatment of ms with goat serum |
| 08/01/2013 | US20130195883 Use of vap-1 inhibitors for treating fibrotic conditions |
| 08/01/2013 | US20130195882 Mcpip protection against osteoclast production |
| 08/01/2013 | US20130195879 Oxadiazole inhibitors of leukotriene production for combination therapy |
| 08/01/2013 | US20130195874 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| 08/01/2013 | US20130195870 ERBB3 Mutations In Cancer |
| 08/01/2013 | US20130195868 Treating surface of the eye disorders |
| 08/01/2013 | US20130195863 Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases |
| 08/01/2013 | US20130195858 Treatment of b-cell lymphoma with microrna |
| 08/01/2013 | US20130195856 Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| 08/01/2013 | US20130195852 Use of inhibitors of bruton's tyrosine kinase (btk) |
| 08/01/2013 | US20130195848 Imidazopyrazines |
| 08/01/2013 | US20130195847 Treatment with anti-vegf antibodies |
| 08/01/2013 | US20130195840 Therapeutics and processes for treatment of immune disorders |
| 08/01/2013 | US20130195827 Nutrigenomic methods to overcome carbohydrate bingeing and overeating |
| 08/01/2013 | US20130195824 Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions |
| 08/01/2013 | US20130195816 Compositions to effect neuronal growth |
| 08/01/2013 | US20130195803 Bovine milk oligosaccharides |
| 08/01/2013 | US20130195801 Cns targeting aav vectors and methods of use thereof |
| 08/01/2013 | US20130195798 Combination therapy for treatment of viral infections |
| 08/01/2013 | US20130195797 High potency formulations of vx-950 |
| 08/01/2013 | US20130195796 Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens |
| 08/01/2013 | US20130195792 Method of treating inflammation |
| 08/01/2013 | US20130195780 Skin Care Products Contianing Anatabine Or Derivative Thereof |
| 08/01/2013 | US20130195771 Gantrez Hydrogel With Dry Tack |
| 08/01/2013 | US20130195770 Composition and method for reducing atherosclerotic lesions |
| 08/01/2013 | US20130195769 Oleaginous pharmaceutical and cosmetic foam |
| 08/01/2013 | US20130195765 Method for treating and diagnosing cancer by using cell-derived microvesicles |
| 08/01/2013 | US20130195763 Methods and compositions for improving sleep and memory |
| 08/01/2013 | US20130195753 Temporary Embolization Using Inverse Thermosensitive Polymers |
| 08/01/2013 | US20130195751 Self-assembed conjugate and use thereof |
| 08/01/2013 | US20130193028 Water-soluble meloxicam granules |
| 08/01/2013 | CA2862535A1 Substituted pyrano and furanoquinolines, their preparation and use as medicaments |
| 08/01/2013 | CA2862532A1 New pharmaceutical compositions containing phosphatidylserine and curcumin |
| 08/01/2013 | CA2862492A1 Methods of treatment of cancer |
| 08/01/2013 | CA2862030A1 Apoptosis signal-regulating kinase inhibitor |
| 08/01/2013 | CA2861464A1 Proteasome activity modulating compounds |
| 08/01/2013 | CA2861462A1 Proteasome activity enhancing compounds |
| 08/01/2013 | CA2861324A1 Transdermal hormone delivery |
| 08/01/2013 | CA2861045A1 Novel compounds, their manufacture and uses (ii) |